Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Shares Acquired by Barclays PLC

Barclays PLC grew its holdings in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Free Report) by 349.2% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 184,189 shares of the company's stock after acquiring an additional 143,184 shares during the quarter. Barclays PLC owned about 0.07% of Maravai LifeSciences worth $1,531,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in MRVI. Creative Planning lifted its position in Maravai LifeSciences by 4.4% in the third quarter. Creative Planning now owns 44,943 shares of the company's stock valued at $373,000 after acquiring an additional 1,881 shares during the last quarter. Kornitzer Capital Management Inc. KS increased its position in shares of Maravai LifeSciences by 0.7% during the third quarter. Kornitzer Capital Management Inc. KS now owns 519,890 shares of the company's stock worth $4,320,000 after purchasing an additional 3,725 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Maravai LifeSciences in the 2nd quarter valued at about $32,000. Venturi Wealth Management LLC acquired a new stake in shares of Maravai LifeSciences in the 3rd quarter valued at about $47,000. Finally, Orion Portfolio Solutions LLC boosted its position in shares of Maravai LifeSciences by 4.8% in the 3rd quarter. Orion Portfolio Solutions LLC now owns 135,749 shares of the company's stock valued at $1,128,000 after purchasing an additional 6,177 shares during the period. Hedge funds and other institutional investors own 50.25% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. Wolfe Research started coverage on Maravai LifeSciences in a research note on Thursday, November 14th. They issued a "peer perform" rating for the company. Robert W. Baird reduced their price target on shares of Maravai LifeSciences from $10.00 to $9.00 and set an "outperform" rating for the company in a research report on Friday, November 8th. The Goldman Sachs Group cut shares of Maravai LifeSciences from a "neutral" rating to a "sell" rating and decreased their price target for the stock from $7.00 to $4.25 in a research note on Thursday, December 5th. Royal Bank of Canada reduced their target price on shares of Maravai LifeSciences from $17.00 to $13.00 and set an "outperform" rating for the company in a report on Friday, November 8th. Finally, William Blair reiterated a "market perform" rating on shares of Maravai LifeSciences in a research note on Friday, November 8th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $10.28.

Insider Buying and Selling at Maravai LifeSciences

In related news, insider Carl Hull bought 175,000 shares of the firm's stock in a transaction on Monday, November 11th. The shares were bought at an average cost of $5.64 per share, for a total transaction of $987,000.00. Following the transaction, the insider now owns 175,000 shares of the company's stock, valued at approximately $987,000. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. 0.63% of the stock is owned by corporate insiders.

Maravai LifeSciences Stock Performance

Shares of Maravai LifeSciences stock traded down $0.11 on Friday, reaching $5.50. 1,114,643 shares of the stock were exchanged, compared to its average volume of 2,205,006. The firm has a market capitalization of $1.39 billion, a PE ratio of -3.35 and a beta of -0.08. Maravai LifeSciences Holdings, Inc. has a 1-year low of $4.28 and a 1-year high of $11.56. The business has a fifty day moving average price of $6.01 and a two-hundred day moving average price of $7.51. The company has a current ratio of 10.74, a quick ratio of 9.94 and a debt-to-equity ratio of 0.89.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.